Ciprofibrate
CARDIOVASCULAR SYSTEM
Also known as: lipanor, oroxadin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ciprofibrate is a drug catalogued in DrugCentral. It was first approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 2009. DrugCentral lists 1 molecular target, including PPARA. Recorded indications include Hypertriglyceridemia and Mixed hyperlipidemia.
- Molecular targets: PPARA (1 listed in DrugCentral).
- Indications: Hypertriglyceridemia and Mixed hyperlipidemia.
- ATC code: C10AB08 (Fibrates).
- Molecular formula: C13H14Cl2O3; molecular weight 289.15 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Hypertriglyceridemia
- Mixed hyperlipidemia
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Peroxisome proliferator-activated receptor alpha | PPARA | agonist | EC50 6.05 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2009-06-18 | UK Medicines and Healthcare Products Regulatory Agency (MHRA) | — | Winthrop Pharmaceuticals UK Limited |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C10AB08 | CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Fibrates |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Mucosal pain | 43.4 |
| Tongue eruption | 36.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ciprofibrate is on its molecule page.
| Molecular formula | C13H14Cl2O3 |
|---|---|
| Molecular weight | 289.15 g/mol |
| CAS number | 52214-84-3 |
| InChIKey | KPSRODZRAIWAKH-UHFFFAOYSA-N |
| PubChem CID | 2763 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ciprofibrate used for?
DrugCentral lists the following indications for Ciprofibrate: Hypertriglyceridemia and Mixed hyperlipidemia.
How does Ciprofibrate work?
Its molecular targets in DrugCentral include PPARA (agonist).
When was Ciprofibrate first approved?
Ciprofibrate was first approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 2009.
What is the chemical formula of Ciprofibrate?
Ciprofibrate has the molecular formula C13H14Cl2O3 and a molecular weight of 289.15 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 658 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL557555 — compound record and bioactivity
- PubChem CID 2763 — chemical identifiers
- DrugBank DB09064 — drug record
- FDA UNII F8252JGO9S — substance identity
- UniProt Q07869 (PPARA) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.